Tesamorelin

FDA Approved

Also known as: Egrifta, TH9507

Growth Hormone PeptidesSubcutaneous

A synthetic GHRH analog FDA-approved for reducing excess abdominal fat in HIV-associated lipodystrophy. Also studied for cognitive benefits and NAFLD.

Molecular Weight5135.9 Da

Half-Life (t½)~26 minutes (but sustained GH elevation)

SequenceModified GHRH (1-44) with trans-3-hexenoic acid

Mechanism of Action

Stimulates pituitary GH release in a physiological pulsatile pattern. The trans-3-hexenoic acid modification improves receptor binding and stability.

Dosing Protocol

2mg subcutaneous daily, typically injected in the abdomen.

Open peptide calculator

Reconstitution

2mg vial + 2mL sterile water (provided with kit).

Storage

Lyophilized: room temperature. Reconstituted: use immediately or refrigerate.

Side Effects

●Injection site reactions
●Joint pain
●Peripheral edema
●Paresthesia

Key Research Findings

●FDA-approved: reduced visceral adipose tissue by 15% in HIV patients
●Improved cognitive function in older adults (GROW study)
●Reduced liver fat in NAFLD pilot studies

Latest Verified Lab Report

No lab reports available for Tesamorelin yet.

Community-funded testing results will appear here.

Vendor Trust Leaderboard

For Tesamorelin

Trust leaderboard coming soon.

Vendor rankings based on verified lab test results.

Active Deals

Gen Peptide

10% OFF

Shop Vendor